Anzeige
Mehr »
Donnerstag, 22.01.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40R3V | ISIN: KYG0705H1039 | Ticker-Symbol:
NASDAQ
21.01.26 | 22:00
1,140 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
BAIRD MEDICAL INVESTMENT HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
BAIRD MEDICAL INVESTMENT HOLDINGS LTD 5-Tage-Chart

Aktueller Chart BAIRD MEDICAL Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
BAIRD MEDICAL INVESTMENT HOLDINGS LTD-Investoren interessieren sich auch für diese Wertpapiere
PAVmed Inc.: PAVmed Announces Reverse Stock SplitNEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating...
► Artikel lesen
PAVmed Inc.: PAVmed Provides Business Update and Reports Third Quarter 2025 Financial ResultsVeris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent...
► Artikel lesen
PAVmed Inc.: PAVmed Provides Business Update and Reports Second Quarter 2025 Financial ResultsLucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million,and secured CAC meeting on Medicare LCD for EsoGuard to be held on September4 Veris...
► Artikel lesen
Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery DiseaseLesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN...
► Artikel lesen
Heartflow, Inc.: Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis PlatformMOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received...
► Artikel lesen
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesMOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its...
► Artikel lesen
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from MedtronicMINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR), a global structural heart company committed...
► Artikel lesen
Anteris Technologies Global Corp.: Anteris Announces Results for the Third Quarter of 2025MINNEAPOLIS, Minn. and BRISBANE, Australia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed...
► Artikel lesen
Anteris Technologies Global Corp.: Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial")MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company...
► Artikel lesen